Bifonazole in vitro activity and its azole-parallel resistance in clinical yeast isolates

摘要: The susceptibility/resistance profile of bifonazole (BFZ) in 170 dermatophyte strains including azole parallel-resistance 324 clinical yeast isolates was determined, additionally with impact on patient-relevant factors. Overall susceptibility to four azoles tested parallel 70%, differences both, the azoles, and species-specific for from patients superficial or invasive/systemic infections. 86% C. glabrata (n=166) were susceptible bifonazole, 76% BFZ-susceptible fluconazole-resistant (n=184) isolates, whereas 45% bifonazole-resistant (n=82) FLC. However, compared voriconazole most other non-C. albicans Candida, non-Candida species less (< 50%) bifonazole. As tested, BFZ showed bimodular MIC-distribution. Susceptibility pattern analysis (SPA) demonstrated that antifungal agent pretreated had zero significant complete (SP: SSSS) non-treated patients. Furthermore, SPA revealed fourfold parallel-resistance, species-specifically distributed, prominently parapsilosis. Evaluation two-way hierarchical clustering a high grade diversity heterogeneity among isolates. A modified MIC assessment system introduced achieve more realistic, well-arranged, therapy oriented reporting vitro data.